Targeted Strategies for Today's Evolving Markets

MissionIR Blog

ContraVir Pharmaceuticals (CTRV) Presents at Rodman & Renshaw Conference

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) operates as a biopharmaceutical company focused on developing targeted antiviral therapies. The company has two drug candidates in clinical studies. The first, FV-100, is now in phase III trials and being developed for the treatment of herpes zoster, or shingles and shingle pain. The second, CMX157, is a highly potent analog of the successful antiviral drug tenofovir DF (Viread). For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.